Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 13,67 € (+111,94 %). La mediana es de 13,67 € (+111,94 %).

Comprar
  11
Mantener
  2
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Evolus beats Q2 2026 revenue forecast and raises full-year target

    Evolus reported Q2 2026 revenue of $84.1m (+21% y/y), beating analysts' estimates and raising the lower end of its full-year revenue guidance to $330m. Adjusted EBITDA was positive at $4.7m for the third consecutive quarter, although EPS of -$0.12 was more negative than expected. Management emphasized portfolio diversification through Evolysse and Profhilo and additional product launches; the stock rose about 5.7% in after-hours trading. » Más en de.investing.com


  • Evolus enters exclusive license and distribution agreement for Profhilo in the US

    Evolus has reached an exclusive license and distribution agreement with Swiss pharmaceutical company IBSA for the skin injection Profhilo in the US. Evolus will assume the development activities required for US approval and will market the product after approval; the agreement includes no upfront payments and is based on a transfer-pricing model. The company expects no impact from the agreement on its 2026 guidance or on the revenue and profitability targets for 2028. Profhilo, a superficially acting hyaluronic acid formulation to improve skin quality, has already been used in millions of treatments worldwide since 2015 and complements Evolus' existing portfolio such as Jeuveau and Evolysse. » Más en de.investing.com


  • Evolus: shareholders reelect Brady Stewart and Vikram Malik and approve executive compensation

    At Evolus' annual general meeting, Brady Stewart and Vikram Malik were reelected as Class II directors for three years. Shareholders confirmed Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and voted in a non-binding advisory vote to approve the compensation of the named executive officers. Additionally, the company reported mixed Q1 results (EPS missed, revenue slightly above expectations) and plans the European launch of the Estyme dermal filler line. » Más en de.investing.com


  • Evolus to launch Estyme dermal filler line in Europe on May 16

    Evolus will introduce the Estyme collection of four injectable hyaluronic acid gels in Europe on May 16, including the globally first commercially available Estyme Sculpt for mid‑face volume restoration. The products are CE‑certified and use Symatese’s Cold‑X technology; FDA approval for Estyme Sculpt is expected later this year. Evolus reported revenue of $301.79 million for the twelve months to Q1 2026 (≈+10%) but remains unprofitable with a negative EPS of -$0.67. » Más en de.investing.com


  • Evolus: Jeuveau drives sales, Evolysse fillers show superiority in approval studies

    Evolus presented comprehensive clinical data for its two-pronged approach with Jeuveau and the new Evolysse filler portfolio based on Cold-X™ technology. U.S. approval-relevant studies show that Evolysse Form and Smooth were not only non-inferior but statistically superior to Restylane-L at six months; Evolysse Sculpt achieved non-inferiority and high responder rates for volume augmentation. Jeuveau delivered solid Phase III results versus Botox and data on a higher‑dose formulation with longer duration; safety profiles remained favorable. On the financial side, Evolus reported Q1 revenue of $73.1 million, reaffirmed full-year guidance and is targeting continued double-digit revenue growth and positive adjusted EBITDA. » Más en de.investing.com

En 2022, Evolus ya ha pagado 0,26 € en dividendos. El último pago fue en marzo de 2022.

Datos financieros de la empresa

En el último trimestre, Evolus tuvo unos ingresos de 68,82 M € y un beneficio neto de -11,05 M €
(EUR) septiembre de 2026
YoY
Ingresos 68,82 M 17,10 %
Beneficio bruto 44,75 M 14,56 %
Beneficio neto -11,05 M 17,60 %
EBITDA -5,66 M 27,81 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
426,51 M €
Número de acciones
66,19 M
Máximo/mínimo de 52 semanas
8,49 € - 3,52 €
Dividendos No
Beta
1,34
Ratio P/E
-15,11
Ratio PEG
-0,20
Ratio P/B
-12,36
Ratio P/S
1,44

Perfil de la empresa

Evolus, Inc., una empresa de belleza de alto rendimiento, ofrece productos de estética médica para médicos y sus pacientes en los Estados Unidos. Ofrece Jeuveau, una formulación propietaria de toxina botulínica tipo A purificada de 900 kilodaltons para la mejora temporal de la apariencia de las líneas glabelares moderadas a severas en adultos. La empresa se constituyó en 2012 y tiene su sede en Newport Beach, California.

Nombre
Evolus
CEO
David Moatazedi
Sede Newport Beach, ca
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
08/02/2018
Empleados 353

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
EOLS
London Stock Exchange
0K16.L
Frankfurt
EVL.F
Düsseldorf
EVL.DU
London
0K16.L
München
EVL.MU
🍪

Parqet  usa cookies. Más información